前庭动和痴呆症:关注共享的病理生理机制和治疗影响
Giovanni Carbone1, Erica Ercolano1, Leonardo Bencivenga1
1Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Journal of the American Medical Directors Association
|February 15, 2024
概括
心房动 (AF) 通过炎症和血液流量减少等共享机制增加痴呆风险. 在AF患者中查认知障碍至关重要,但需要对治疗方法进行更多研究.
科学领域:
- 老年病学和神经病学
- 心血管研究研究心血管研究
背景情况:
- 在老年人中,心房动 (AF) 和痴呆症是普遍存在的,使人衰弱的疾病.
- 在AF和痴呆症风险增加之间存在显著的关联.
- 了解共享的病理生理路径是管理这些疾病的关键.
研究的目的:
- 审查关联心房动和痴呆的常见病理生理机制.
- 探索潜在的治疗策略,以预防AF患者的认知衰退.
主要方法:
- 现有文学作品的叙述性回顾.
- 包括流行病学,观察和干预研究.
- 从2022年12月到2023年5月进行的文献搜索.
主要成果:
- 心房动与痴呆的风险增加有关,尽管亚型各不相同.
- 确定的常见机制包括血栓栓塞,炎症,感染,低 perfusion,和大脑缩.
- 审查了对AF患者痴呆症预防治疗干预措施的证据.
结论:
- 由于共同的风险因素和机制,对AF患者进行认知查至关重要.
- 需要进一步的研究来确定抗不律性和抗凝固疗法对AF认知结果的影响.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Mechanism of Cardiac Arrhythmias
920
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
920
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431


